Early Decisions To De-Risk The Transition To Combination Products


There is constant pressure to accelerate drug development timelines, which means always keeping an eye on costs and quality while navigating regulatory requirements.

There is no longer the option to speed the process through a less optimized containment and delivery system. Expectations and the competitive environment are changing in relation to three key factors: self administration, ease of use, and competition.

To address these changes, one could focus solely on drug development and risk unforeseen obstacles by leaving combination product and device considerations to later phases. Alternately, one could go to market with a simple containment system, but it may not meet patient needs. Finally, one could rely on multiple outsourcing partners to develop a combination product, which could complicate planning and lead to costly delays.

Download the full PDF to explore what you can do to overcome all this uncertainty and risk in injectable product development.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Med Device Online? Subscribe today.

Subscribe to Med Device Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Med Device Online

West Pharmaceutical Services, Inc.